These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27528240)

  • 1. Using Immune Checkpoint Inhibitors in Lung Cancer.
    Marrone KA; Brahmer JR
    Oncology (Williston Park); 2016 Aug; 30(8):713-21. PubMed ID: 27528240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
    Cheng M; Durm G; Hanna N; Einhorn LH; Kong FS
    Future Oncol; 2017 Dec; 13(28):2503-2505. PubMed ID: 29168656
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
    Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
    Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Shien K; Papadimitrakopoulou VA; Wistuba II
    Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
    Rihawi K; Gelsomino F; Sperandi F; Melotti B; Fiorentino M; Casolari L; Ardizzoni A
    Ther Adv Respir Dis; 2017 Sep; 11(9):353-373. PubMed ID: 28818019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
    Bianco A; Perrotta F; Barra G; Malapelle U; Rocco D; De Palma R
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
    Goldberg SB; Herbst RS
    Cancer; 2018 Dec; 124(24):4592-4596. PubMed ID: 30383887
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
    Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
    J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.